We found that AD 198 potently decreased protein levels of c-Myc, which was primarily localized in the nucleus, in a dose-dependent manner at 6 hours after treatment in TRAF3-/- mouse B lymphoma and human MM cells (Figure 7A). Here, TRAF3 is linked to Miyoshi myopathy.